Enone cancer therapeutics

Details Enone cancer therapeutics Enone cancer therapeutics

2004-12-07

2009-08-04

Qazi, Sabiha N. (Department: 1612)

Organic compounds -- part of the class 532-570 series

Organic compounds

Fatty compounds having an acid moiety which contains the...

C554S119000, C568S037000

Reexamination Certificate

active

07569711

ABSTRACT:
Described herein are new enone derivatives and conjugates. Additionally, methods for synthesizing these new enones are also disclosed. These compounds can be employed in cancer therapy.

REFERENCES:
Aghil et al. (DN 116:227668, HCAPLUS, abstract of Anti Cancer Drug Design (1992), 7(1), 67-82).
Izawa et al. (DN 106:49660, HCAPLUS, abstract of JP 61134340).
Tsuji et al. (DN 108:111864, HCAPLUS, abstract of JP 62129235).
Diana S. Hamilton, et al., “Glutathionyl Transferase Catalyzed Addition of Glutathione to COMC: A New Hypothesis for Antitumor Activity”,Organic Letters 2002, vol. 4, No. 7, 1209-1212; published on Web Mar. 3, 2002.
Aghil et al., “Synthesis and Cytotoxicity of Shikimate Analogues. Structure: Activity Studies Based on 1-Crotonyloxymethyl-3R, 4R, 5R-trihydroxycyclohex-2-enone,” Anti-Cancer Drug Design, pp. 67-82 (1992).
Chimura et al., “The Structure of a Glyoxalase I Inhibitor and Its Chemical Reactivity with SH-Compounds,” The Journal of Antibiotics, pp. 743-748 (1975).
Hamilton et al., “Glutathionyl Transferase Catalyzed Addition of Glutathione to COMC: A New Hypothesis for Antitumor Activity.”
Huntley et al., “A New Synthesis of the Glyoxalase-I Inhibitor COTC,” Tetrahedron Letters, pp. 2031-2034 (2000).
Huntley et al., “Reaction of COTC with Glutathione: Structure of the Putative Glyoxalase I Inhibitor,” Organic Letters, pp. 3143-3144 (2000).
Jones et al., “Target Directed Enediyne Prodrugs: Cytotoxic Estrogen Conjugates,” Tetrahedron Letters, pp. 3643-3646 (1996).
Kavarana et al., “Mechanism-Based Competitive Inhibitors of Glyoxalase I: Intracellular Deliver, in Vitro Antitumor Activities, and Stabilities in Human Serum and Mouse Serum,” J. Med. Chem., pp. 221-228 (1999).
Kuduk et al., “Synthesis and Evaluation of Geldanamycin-Testosterone Hybrids,” Bioorganic & Medicinal Chemistry Letters, pp. 1303-1306 (2000).
Kuduk et al., “Synthesis and Evaluation of Geldanamycin-Estradiol Hybrids,” Bioorganic & Medicinal Chemistry Letters, pp. 1233-1238 (1999).
Lu et al., “Design of Novel Bioconjugates for Targeted Drug Delivery,” Journal of Controlled Release, pp. 165-173 (2002).
Maeda et al., “Conjugates of Anticancer Agents and Polymers: Advantages of Macromolecular Therapeutics in Vivo,” Bioconjugate Chemistry, pp. 353-362 (1992).
Mirza et al., “Synthesis of a Glyoxalase I Inhibitor fromStreptomyces griseosporeus. .,” Helvetica Chimica Acta, pp. 988-996 (1985).
Rezgui et al., “DMAP-Catalyzed Hydroxymethylation of 2-Cyclohexenones in Aqueous Medium Through Baylis-Hillman Reaction,” Tetrahedron Letters, pp. 5965-5966 (1998).
Takeuchi et al., “A Glyoxalase I Inhibitor of a New Structural Type Produced byStreptomyces,” The Journal of Antibiotics, pp. 737-742 (1975).
Tamura et al., “Asymmetric Synthesis of 3-Substituted 2-exo-Methylenealkanones by Addition-Elimination Reaction Using a Chiral Leaving Group and Organometallic Nucleophiles,” J. Org. Chem., pp. 4895-4903 (1992).
Tamura et al., “Stereoselective Synthesis of Cis 2,3-Disu stituted Cycloheptanones by Kinetic Protonation,” American Chemical Society, p. 4903 (1992).

Affiliated with

Also associated with

Rating

Enone cancer therapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enone cancer therapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enone cancer therapeutics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4055966